Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):997-1000. doi: 10.1051/medsci/2019197. Epub 2020 Jan 6.

[Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives].

[Article in French; Abstract available in French from the publisher]

Author information

1
Département de Cancérologie de l'enfant et de l'adolescent, Gustave Roussy, 94800 Villejuif, France.

Abstract

in English, French

Neuroblastoma is the most frequent extra-cranial pediatric solid tumor, occurring in young children, 90% being less than 5 years at diagnosis. It remains a therapeutic challenge since survival of high-risk neuroblastoma patients that represent around 50% of the patients is around 50% in spite of extensive combined treatments. Immunotherapy based on the use of antibodies directed to GD2, a ganglioside strongly expressed by almost all neuroblastoma cells, has been developed during the last decade. In SIOPEN studies have shown that dinatuximab beta (Qarziba®) is effective on refractory/relapsed patients and improves survival when administered in the first line maintenance treatment. Other strategies are currently explored using combination with chemotherapy at relapse and evaluating the benefits of an earlier administration during the induction treatment. In addition, more selective antibodies are also developed to decrease toxicity, especially neuropathic pain that is one of the major toxic effect.

PMID:
31903906
DOI:
10.1051/medsci/2019197

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center